Next year, the company will pursue regulatory clearance for its wearable device, CardioTag. The company’s first application using artificial intelligence to improve the management of congestive heart failure, according to a Dec. 8 Cardiosense news release.
The financing round was co-led by Broadview Ventures and Hatteras Venture Partners. Cardiosense plans to use the financing to expand its team, accelerate product development and fund a heart failure study.
